Paricalcitol, a synthetic vitamin D analog

A candidate for combination therapy with biological agents in rheumatoid arthritis

Tae Hwan Kim, Jong Dae Ji

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Biologic agents, especially TNFα inhibitors, appear to be very effective in treatment of rheumatoid arthritis (RA). Although the use of biologic agents has greatly improved the therapeutic efficacy in management of RA, biologic therapies for RA treatment have several limitations. These agents fail to achieve complete remission in substantial portion of RA patients. Also certain adverse events have been observed, including serious bacterial infections and reactivation of latent tuberculosis. Previous reports demonstrated that TNFα inhibitors are more efficacious in combination with other drugs such as methotrexate. In this report, we suggest that paricalcitol, a synthetic vitamin D analog is another candidate molecule for combination therapy with TNFα inhibitors in RA.

Original languageEnglish
Pages (from-to)634-635
Number of pages2
JournalMedical Hypotheses
Volume75
Issue number6
DOIs
Publication statusPublished - 2010 Dec 1

Fingerprint

Biological Factors
Vitamin D
Rheumatoid Arthritis
Latent Tuberculosis
Therapeutics
Biological Therapy
Bacterial Infections
Methotrexate
paricalcitol
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Paricalcitol, a synthetic vitamin D analog : A candidate for combination therapy with biological agents in rheumatoid arthritis. / Kim, Tae Hwan; Ji, Jong Dae.

In: Medical Hypotheses, Vol. 75, No. 6, 01.12.2010, p. 634-635.

Research output: Contribution to journalArticle

@article{ccfbb40c91e3444682f02161e5b8f5f1,
title = "Paricalcitol, a synthetic vitamin D analog: A candidate for combination therapy with biological agents in rheumatoid arthritis",
abstract = "Biologic agents, especially TNFα inhibitors, appear to be very effective in treatment of rheumatoid arthritis (RA). Although the use of biologic agents has greatly improved the therapeutic efficacy in management of RA, biologic therapies for RA treatment have several limitations. These agents fail to achieve complete remission in substantial portion of RA patients. Also certain adverse events have been observed, including serious bacterial infections and reactivation of latent tuberculosis. Previous reports demonstrated that TNFα inhibitors are more efficacious in combination with other drugs such as methotrexate. In this report, we suggest that paricalcitol, a synthetic vitamin D analog is another candidate molecule for combination therapy with TNFα inhibitors in RA.",
author = "Kim, {Tae Hwan} and Ji, {Jong Dae}",
year = "2010",
month = "12",
day = "1",
doi = "10.1016/j.mehy.2010.08.003",
language = "English",
volume = "75",
pages = "634--635",
journal = "Medical Hypotheses",
issn = "0306-9877",
publisher = "Churchill Livingstone",
number = "6",

}

TY - JOUR

T1 - Paricalcitol, a synthetic vitamin D analog

T2 - A candidate for combination therapy with biological agents in rheumatoid arthritis

AU - Kim, Tae Hwan

AU - Ji, Jong Dae

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Biologic agents, especially TNFα inhibitors, appear to be very effective in treatment of rheumatoid arthritis (RA). Although the use of biologic agents has greatly improved the therapeutic efficacy in management of RA, biologic therapies for RA treatment have several limitations. These agents fail to achieve complete remission in substantial portion of RA patients. Also certain adverse events have been observed, including serious bacterial infections and reactivation of latent tuberculosis. Previous reports demonstrated that TNFα inhibitors are more efficacious in combination with other drugs such as methotrexate. In this report, we suggest that paricalcitol, a synthetic vitamin D analog is another candidate molecule for combination therapy with TNFα inhibitors in RA.

AB - Biologic agents, especially TNFα inhibitors, appear to be very effective in treatment of rheumatoid arthritis (RA). Although the use of biologic agents has greatly improved the therapeutic efficacy in management of RA, biologic therapies for RA treatment have several limitations. These agents fail to achieve complete remission in substantial portion of RA patients. Also certain adverse events have been observed, including serious bacterial infections and reactivation of latent tuberculosis. Previous reports demonstrated that TNFα inhibitors are more efficacious in combination with other drugs such as methotrexate. In this report, we suggest that paricalcitol, a synthetic vitamin D analog is another candidate molecule for combination therapy with TNFα inhibitors in RA.

UR - http://www.scopus.com/inward/record.url?scp=77958457182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958457182&partnerID=8YFLogxK

U2 - 10.1016/j.mehy.2010.08.003

DO - 10.1016/j.mehy.2010.08.003

M3 - Article

VL - 75

SP - 634

EP - 635

JO - Medical Hypotheses

JF - Medical Hypotheses

SN - 0306-9877

IS - 6

ER -